Severe Cutaneous Adverse Reaction Caused by Carbamazepine and Levofloxacin After Varicella Zoster Virus Infection

被引:1
作者
Wang, Meifang [1 ]
Lin, Li [1 ]
Wang, Leyi [1 ]
Li, Linfeng [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Dermatol, Beijing, Peoples R China
来源
INFECTION AND DRUG RESISTANCE | 2023年 / 16卷
关键词
severe cutaneous adverse reaction; SCARs; acute generalized exanthematous pustulosis; AGEP; drug reaction with eosinophilia and systematic syndrome; DRESS syndrome; overlapping feature; carbamazepine; varicella zoster virus infection;
D O I
10.2147/IDR.S402267
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Severe cutaneous adverse reactions (SCARs) to drugs are associated with morbidity, mortality, healthcare costs, and challenges in drug development. It is important to identify the SCAR type early by using strict diagnostic criteria because they may require different treatments, follow-ups, and short- or long-term prognoses. A 68-year-old woman admitted to our hospital presented with fever and rashes for 10 days. This case exhibited many features that suggested acute generalized exanthematous pustulosis (AGEP). However, the course of treatment and verified clinical features led to a diagnosis of AGEP and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome that was induced by carbamazepine and levofloxacin after a herpes zoster infection. AGEP combined with DRESS syndrome is a complicated and rare drug-induced dermatological eruption that follows a course similar to DRESS syndrome and more recalcitrant than the course seen with typical AGEP. The associated factors for the SCARs in our patient included age, history of allergy, viral infection, and drugs interacting with specific HLA loci. Improving our understanding of these factors can improve the treatment and prevention of SCARs in these patients.
引用
收藏
页码:1705 / 1711
页数:7
相关论文
共 22 条
[1]   Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist? [J].
Bouvresse, Sophie ;
Valeyrie-Allanore, Laurence ;
Ortonne, Nicolas ;
Konstantinou, Marie Pauline ;
Kardaun, Sylvia H. ;
Bagot, Martine ;
Wolkenstein, Pierre ;
Roujeau, Jean-Claude .
ORPHANET JOURNAL OF RARE DISEASES, 2012, 7
[2]   Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome [J].
Cardones, Adela R. .
CLINICS IN DERMATOLOGY, 2020, 38 (06) :702-711
[3]   Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? [J].
Gey, A. ;
Milpied, B. ;
Dutriaux, C. ;
Mateus, C. ;
Robert, C. ;
Perro, G. ;
Taieb, A. ;
Ezzedine, K. ;
Jouary, T. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (01) :178-179
[4]   Overlapping acute generalized exanthematous pustulosis drug reaction with eosinophilia and systemic symptoms induced by a second dose of the Moderna COVID-19 vaccine [J].
Ikeda, Takaharu ;
Yokoyama, Kae ;
Kawakami, Tamihiro .
JOURNAL OF DERMATOLOGY, 2022, 49 (12) :E446-E447
[5]   Piperacillin/Tazobactam-Associated Hypersensitivity Syndrome with Overlapping Features of Acute Generalized Exanthematous Pustulosis and Drug-Related Rash with Eosinophilia and Systemic Symptoms Syndrome [J].
Kim, Tae In ;
Jeong, Ki Heon ;
Shin, Min Kyung ;
Kim, Nack In .
ANNALS OF DERMATOLOGY, 2016, 28 (01) :98-101
[6]   Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS) [J].
Miyagawa, Fumi ;
Asada, Hideo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) :1-13
[7]   Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy [J].
Mockenhaupt, Maja .
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (02) :142-160
[8]  
Perello M I, 2022, Eur Ann Allergy Clin Immunol, V54, P207, DOI 10.23822/EurAnnACI.1764-1489.193
[9]   SEVERE ADVERSE CUTANEOUS REACTIONS TO DRUGS [J].
ROUJEAU, JC ;
STERN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (19) :1272-1285
[10]   Updates and Insights in the Diagnosis and Management of DRESS Syndrome [J].
Schunkert, Elisa Maria ;
Divito, Sherrie Jill .
CURRENT DERMATOLOGY REPORTS, 2021, 10 (04) :192-204